Therefore, to give the first evidence about the potential of autoantibodies to VEGFR-3 as NIBMs of BDL-induced liver injury, cholestasis, and fibrosis, we performed correlations between absorbances associated with the serum levels of autoantibodies to VEGFR-3, obtained in the ELISA, and a panel of traditional markers of liver injury (AST and ALT), cholestasis (TB), and fibrosis (relative fibrotic area). Here, FLT4 is linked to cholestasis.